Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: Primary outcome of the EXTEND III study

Acta Ophthalmologica

Volumn 90, Issue 5, 2012, Pages

  Lee, Fenq Lih ^a   Kwon, Oh Woong ^b   Chung, Hum ^c   Lai, Chi Chun ^d   Sheu, Shwu Jiuan ^e   Yoon, Young Hee ^f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NUNE Eye Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN A;

AGED; BEST CORRECTED VISUAL ACUITY; CATARACT; CONJUNCTIVAL HEMORRHAGE; DRUG APPROVAL; DRUG SAFETY; ENZYME INHIBITION; ETHNIC GROUP; HUMAN; INJECTION SITE PAIN; INTRAOCULAR PRESSURE; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RETINA EXUDATE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RHINOPHARYNGITIS; SIDE EFFECT; SOUTH KOREAN; STUDY DESIGN; SUBRETINAL NEOVASCULARIZATION; TAIWANESE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS FLOATERS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; INTRAVITREAL INJECTIONS; REPUBLIC OF KOREA; SINGLE-BLIND METHOD; TAIWAN; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84864403617     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02262.x     Document Type: Letter

References (4)

1. Brown DM, Michels M, Kaiser PK, et al., (2009): Ranibizumab versus Verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
2. Ferrara N, Damico L, Shams N, Lowman H, &, Kim R, (2006): Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859-870. (Pubitemid 44547437)
3. Rosenfeld PJ, Brown DM, Heier JS, et al., (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
4. Tano Y, &, Ohji M, (2010): EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 3: 309-316.